Citizens Jmp upgraded shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) to a strong-buy rating in a report ...

KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) last posted its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS ...

Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...

JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a small-molecule plasma kallikrein inhibitor, which could ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV). Jonathan Wolleben’s rating is based on several compelling factors that ...

On February 3rd, our Board of Directors approved another tax-efficient share repurchase program of up to 10% of our total shares outstanding, expected to be executed over the next three to six months.

Tesla shares rallied Thursday even after delivering a fourth-quarter earnings report that fell short of expectations and sealed a second consecutive year of declining profits, as investors focused ...

US stocks gained steam on Thursday afternoon as investors digested megacap tech earnings and waited for Apple (AAPL) results for more clues on prospects for Big Tech. Right ahead of the closing ...

An icon in the shape of a lightning bolt. Impact Link Tesla reported fourth-quarter earnings on Wednesday after the closing bell, delivering results that missed Wall Street's expectations.